Compounds of formula I: ##STR00001##
are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

Compounds of formula I: ##STR00001##
are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

Disclosed is a pharmaceutical composition comprising a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a myelin related disorder in a subject, the method comprising administering to the subject an effective amount of a compound of Structural Formula (I) or a pharmaceutical composition comprising the compound of Structural Formula (I). The variables of Structural Formula (I) are described herein.

##STR00001##

The present invention provides a novel compound that increases KAI1 promoter activity, a pharmaceutically acceptable salt thereof, and a composition for inhibiting cancer metastasis and invasion or treating colorectal cancer containing the same.

The present invention provides a novel compound that increases KAI1 promoter activity, a pharmaceutically acceptable salt thereof, and a composition for inhibiting cancer metastasis and invasion or treating colorectal cancer containing the same.

Compounds, compositions, and methods are provided for dual partial agonism of serotonin 5-HTS and 5-HTIA receptors. The enantiomerically pure 5-phenyl-2-aminotetralin (5-PAT) compounds can be used to treat or prevent substance use disorder, opioid use disorder, addiction, anxiety, psychosis, depression, autism spectrum disorder, fragile X syndrome, neurological disorders, neuropsychiatric disorders, repetitive behaviors, movement disorders, compulsions, tics, pain disorders, vasospastic disorders, migraine headache, seizures, epilepsy, social anxiety, addiction withdrawal, drug withdrawal, drug abuse, alcoholism, eating disorders, general inflammation disorders, miosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, and gastrointestinal disorders.

Compounds, compositions, and methods are provided for dual partial agonism of serotonin 5-HTS and 5-HTIA receptors. The enantiomerically pure 5-phenyl-2-aminotetralin (5-PAT) compounds can be used to treat or prevent substance use disorder, opioid use disorder, addiction, anxiety, psychosis, depression, autism spectrum disorder, fragile X syndrome, neurological disorders, neuropsychiatric disorders, repetitive behaviors, movement disorders, compulsions, tics, pain disorders, vasospastic disorders, migraine headache, seizures, epilepsy, social anxiety, addiction withdrawal, drug withdrawal, drug abuse, alcoholism, eating disorders, general inflammation disorders, miosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, and gastrointestinal disorders.

The present application relates to the treatment of nematode infections. For example, the application relates to the use of compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and/or Formula (VI) as defined herein for treatment of a nematode infection or a disease, disorder or condition arising from a nematode infection:

##STR00001##

The present application relates to the treatment of nematode infections. For example, the application relates to the use of compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and/or Formula (VI) as defined herein for treatment of a nematode infection or a disease, disorder or condition arising from a nematode infection:

##STR00001##

Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.